Keros Therapeutics, Inc.
KROS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $642,662 | $542,182 | $413,296 | $638,551 |
| - Cash | $693,472 | $690,215 | $720,541 | $559,931 |
| + Debt | $17,429 | $17,954 | $18,413 | $18,861 |
| Enterprise Value | -$33,381 | -$130,079 | -$288,832 | $97,481 |
| Revenue | $14,262 | $18,168 | $211,246 | $3,042 |
| % Growth | -21.5% | -91.4% | 6,844.3% | – |
| Gross Profit | $13,867 | $17,798 | $211,246 | $2,710 |
| % Margin | 97.2% | 98% | 100% | 89.1% |
| EBITDA | -$8,309 | -$32,548 | $152,384 | -$29,142 |
| % Margin | -58.3% | -179.2% | 72.1% | -958% |
| Net Income | -$7,280 | -$30,696 | $148,451 | -$46,026 |
| % Margin | -51% | -169% | 70.3% | -1,513% |
| EPS Diluted | -0.18 | -0.76 | 3.62 | -1.14 |
| % Growth | 76.3% | -121% | 417.5% | – |
| Operating Cash Flow | $3,249 | -$29,623 | $161,171 | -$46,008 |
| Capital Expenditures | -$132 | -$720 | -$565 | -$289 |
| Free Cash Flow | $3,117 | -$30,343 | $160,606 | -$46,297 |